← Leaderboards
Marina Emborg
Rush University Medical Center
$10,094,272
Attributed
$18,087,322
Total exposure
49
Grants
44
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,087,322 · 49
By mechanism
RF1$3,064,072 · 1
R24$2,721,511 · 1
R01$2,686,818 · 2
UH3$2,404,322 · 1
UG3$2,253,202 · 1
P51$1,803,124 · 40
Top collaborators
- Rui Chen5 shared
- Shaoqin - Gong5 shared
- Jon E Levine5 shared
- Subhojit Roy5 shared
- Krishanu Saha5 shared
- Thaddeus G Golos4 shared
- Ned H Kalin1 shared
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesUnited States National Institutes Of HealthResearch PersonnelSourceFundingGrantParkinson DiseaseInstitutionNonhuman PrimateServicesMacaca MulattaComputer Retrieval Of Information On Scientific Projects DatabasePrimatesBrainAnimalsMonkeysWisconsinImageCellsNeurodegenerative DisordersAlzheimer&AposSafetyIn VivoReporting
Grant awards (64)
Anxiety and depression in a nonhuman primate model of synucleinopathy$3,064,072
RF1 · FY2025 · NS · contact PI
Frontotemporal dementia in rhesus macaques$695,849
R01 · FY2025 · NS · contact PI
Frontotemporal dementia in rhesus macaques$775,469
R01 · FY2024 · NS · contact PI
Modeling Frontotemporal Dementia in Rhesus Macaques$639,563
R33 · FY2024 · NS · contact PI
Modeling Frontotemporal Dementia in Rhesus Macaques$604,886
R33 · FY2023 · NS · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,212,189
UH3 · FY2022 · NS
Modeling Frontotemporal Dementia in Rhesus Macaques$545,322
R33 · FY2022 · NS · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,192,133
UH3 · FY2021 · NS
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2020 · NS
Modeling Frontotemporal Dementia in Rhesus Macaques$470,696
R61 · FY2020 · NS · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2019 · NS
Modeling Frontotemporal Dementia in Rhesus Macaques$488,011
R61 · FY2019 · NS · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$752,280
UG3 · FY2018 · NS
Transgenic marmosets for translational stem cell research$704,329
R24 · FY2018 · OD
Transgenic marmosets for translational stem cell research$670,367
R24 · FY2017 · OD
Transgenic marmosets for translational stem cell research$700,386
R24 · FY2016 · OD
Transgenic marmosets for translational stem cell research$646,429
R24 · FY2015 · OD
Activation of PPAR-gamma in a Monkey Model of Cardiac Dysautonomia$221,710
R21 · FY2015 · NS · contact PI
Activation of PPAR-gamma in a Monkey Model of Cardiac Dysautonomia$184,085
R21 · FY2014 · NS · contact PI
INDIVIDUALIZED STEM CELL THERAPY FOR PARKINSON?S DISEASE$42,964
P51 · FY2011 · RR · contact PI
CONVECTION-ENHANCED DELIVERY OF THERAPEUTIC AGENTS TO THE PUTAMEN$39,092
P51 · FY2011 · RR · contact PI
NEUROPROTECTIVE PROPERTIES OF SELECTIVE PPAR GAMMA AGONIST LY554862$39,092
P51 · FY2011 · RR · contact PI
OPTIMIZING THE DELIVERY OF GENE THERAPY FOR PARKINSON?S DISEASE$15,674
P51 · FY2011 · RR · contact PI
HEART DYSAUTONOMIA IN PARKINSON'S DISEASE$7,837
P51 · FY2011 · RR · contact PI
PRECLINICAL PARKINSON?S RESEARCH PROGRAM$103,269
P51 · FY2010 · RR · contact PI
ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON?S DISEASE$30,981
P51 · FY2010 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 FOR PARKINSON?S DISEASE$30,981
P51 · FY2010 · RR · contact PI
TRANSPLANTATION OF ES CELLS-DERIVED DOPAMINERGIC NEURONS$30,981
P51 · FY2010 · RR · contact PI
CONVECTION-ENHANCED DELIVERY OF THERAPEUTIC AGENTS TO THE PUTAMEN$30,981
P51 · FY2010 · RR · contact PI
NEUROPROTECTIVE PROPERTIES OF SELECTIVE PPAR GAMMA AGONIST LY554862$30,981
P51 · FY2010 · RR · contact PI
PIOGLITAZONE CSF PENETRATION TO TREAT PARKINSON'S DISEASE$30,981
P51 · FY2010 · RR · contact PI
INDIVIDUALIZED STEM CELL THERAPY FOR PARKINSON?S DISEASE$30,981
P51 · FY2010 · RR · contact PI
HEART DYSAUTONOMIA IN PARKINSON'S DISEASE$30,981
P51 · FY2010 · RR · contact PI
OPTIMIZING THE DELIVERY OF GENE THERAPY FOR PARKINSON?S DISEASE$30,981
P51 · FY2010 · RR · contact PI
PRECLINICAL PARKINSON?S RESEARCH PROGRAM$93,766
P51 · FY2009 · RR · contact PI
CONVECTION-ENHANCED DELIVERY OF THERAPEUTIC AGENTS TO THE PUTAMEN$46,835
P51 · FY2009 · RR · contact PI
HEART DYSAUTONOMIA IN PARKINSON'S DISEASE$46,835
P51 · FY2009 · RR · contact PI
DOPAMINERGIC NEURONS FROM IPS CELLS TO TREAT PARKINSON'S DISEASE$46,835
P51 · FY2009 · RR · contact PI
PIOGLITAZONE CSF PENETRATION TO TREAT PARKINSON'S DISEASE$46,835
P51 · FY2009 · RR · contact PI
NEUROPROTECTIVE PROPERTIES OF SELECTIVE PPAR GAMMA AGONIST LY554862$46,835
P51 · FY2009 · RR · contact PI
ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON?S DISEASE$46,835
P51 · FY2009 · RR · contact PI
TRANSPLANTING NEURAL PROGENITOR STEM CELLS EXPRESSING GDNF IN PARKINSON?S$46,835
P51 · FY2009 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 FOR PARKINSON?S DISEASE$46,835
P51 · FY2009 · RR · contact PI
TRANSPLANTATION OF ES CELLS-DERIVED DOPAMINERGIC NEURONS$46,835
P51 · FY2009 · RR · contact PI
TRANSPLANTATION OF ES CELLS-DERIVED DOPAMINERGIC NEURONS$81,915
P51 · FY2008 · RR · contact PI
CONVECTION-ENHANCED DELIVERY OF THERAPEUTIC AGENTS TO THE PUTAMEN$81,915
P51 · FY2008 · RR · contact PI
PRECLINICAL PARKINSON?S RESEARCH PROGRAM$81,915
P51 · FY2008 · RR · contact PI
ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON?S DISEASE$81,915
P51 · FY2008 · RR · contact PI
TRANSPLANTING NEURAL PROGENITOR STEM CELLS EXPRESSING GDNF IN PARKINSON?S$81,915
P51 · FY2008 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 FOR PARKINSON?S DISEASE$81,915
P51 · FY2008 · RR · contact PI
ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON'S DISEASE$31,486
P51 · FY2007 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 FOR PARKINSON'S DISEASE$31,485
P51 · FY2007 · RR · contact PI
TRANSPLANTING NEURAL PROGENITOR STEM CELLS EXPRESSING GDNF IN PARKINSON'S$31,485
P51 · FY2007 · RR · contact PI
TRANSPLANTATION OF ES CELLS-DERIVED DOPAMINERGIC NEURONS$31,485
P51 · FY2007 · RR · contact PI
TRANSPLANTATION OF ES CELLS-DERIVED DOPAMINERGIC NEURONS$27,215
P51 · FY2006 · RR · contact PI
ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON?S DISEASE$27,215
P51 · FY2006 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 FOR PARKINSON?S DISEASE$27,215
P51 · FY2006 · RR · contact PI
TRANSPLANTING NEURAL PROGENITOR STEM CELLS EXPRESSING GDNF IN PARKINSON?S$27,215
P51 · FY2006 · RR · contact PI
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MONKEY MODEL$34,795
P51 · FY2005 · RR
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL$196,000
R01 · FY2003 · NS
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL$90,000
R01 · FY2003 · NS
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL$286,000
R01 · FY2002 · NS
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL$286,000
R01 · FY2001 · NS
LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL$357,500
R01 · FY2000 · NS